Ho Ching ^Investor

Ho Ching is a Vice President at Temasek with a strong background in public and private healthcare investments. With experience in biotech research and a PhD in Biomedical Engineering from UCLA, Ho has a proven track record of developing innovative platforms for drug screening and DNA sequencing. Their expertise in nanoparticle-lipid bilayer interactions has been published in reputable journals. Ho is fluent in Chinese (Mandarin) and English, and is a member of the Bruin Venture Capital Network and China Networking Group. With a Series 87 license from FINRA, Ho is well-equipped to navigate the complexities of the healthcare investment landscape.